These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 29796708)

  • 41. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood.
    Phillips RS; Gopaul S; Gibson F; Houghton E; Craig JV; Light K; Pizer B
    Cochrane Database Syst Rev; 2010 Sep; (9):CD007786. PubMed ID: 20824866
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Management of radiation-induced nausea and vomiting with palonosetron in patients with pre-existing emesis: a pilot study.
    Ganesh V; Chan S; Zhang L; Drost L; DeAngelis C; Wan BA; Pasetka M; Tsao M; Barnes E; Pulenzas N; Chung H; Zaki P; Yee C; Chow E
    Ann Palliat Med; 2018 Oct; 7(4):385-392. PubMed ID: 30180723
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients.
    Navari RM
    Paediatr Drugs; 2017 Jun; 19(3):213-222. PubMed ID: 28447301
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics.
    Hsu ES
    Am J Ther; 2010; 17(5):476-86. PubMed ID: 20844345
    [TBL] [Abstract][Full Text] [Related]  

  • 46. State of the Art Antiemetic Therapy for Cancer Patients.
    Lau TK; Yip CH; Yeo W
    Curr Oncol Rep; 2016 Jan; 18(1):2. PubMed ID: 26694923
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents.
    Navari RM
    Drugs; 2013 Mar; 73(3):249-62. PubMed ID: 23404093
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 2016 updated MASCC/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children.
    Dupuis LL; Sung L; Molassiotis A; Orsey AD; Tissing W; van de Wetering M
    Support Care Cancer; 2017 Jan; 25(1):323-331. PubMed ID: 27565788
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
    Eisenberg P; Figueroa-Vadillo J; Zamora R; Charu V; Hajdenberg J; Cartmell A; Macciocchi A; Grunberg S;
    Cancer; 2003 Dec; 98(11):2473-82. PubMed ID: 14635083
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Experience with the use of palonosetron (onicit) in patients with solid tumors receiving cytostatic therapy].
    Vladimirova LY; Mitashok IS; Storozhakova AE; Kalabanova EA; Svetitskaya YV; Kabanov SN
    Vopr Onkol; 2015; 61(4):653-5. PubMed ID: 26571839
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Translational and Randomized Study of 5-HT3 Receptor Antagonists for Evaluation of Chemotherapy-induced Nausea and Vomiting Related Biomarkers.
    Tsubata Y; Nakao M; Amano Y; Hotta T; Hamaguchi M; Okimoto T; Miura K; Hamaguchi S; Kuraki T; Itakura M; Isobe T
    J Med Invest; 2019; 66(3.4):269-274. PubMed ID: 31656287
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic.
    Hesketh PJ; Palmas M; Nicolas P
    Support Care Cancer; 2018 Apr; 26(4):1151-1159. PubMed ID: 29080920
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting-a systematic review and meta-analysis.
    Chow R; Valdez C; Chow N; Zhang D; Im J; Sodhi E; Lock M
    Support Care Cancer; 2020 May; 28(5):2095-2103. PubMed ID: 31916006
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preventing chemotherapy-induced nausea and vomiting with netupitant/palonosetron, the first fixed combination antiemetic: current and future perspective.
    Aapro M; Zhang L; Yennu S; LeBlanc TW; Schwartzberg L
    Future Oncol; 2019 Apr; 15(10):1067-1084. PubMed ID: 30860400
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prophylaxis of radiation-induced nausea and vomiting using 5-hydroxytryptamine-3 serotonin receptor antagonists: a systematic review of randomized trials.
    Salvo N; Doble B; Khan L; Amirthevasar G; Dennis K; Pasetka M; Deangelis C; Tsao M; Chow E
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):408-17. PubMed ID: 21075553
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recent Advances in Antiemetics: New Formulations of 5-HT3 Receptor Antagonists in Adults.
    Smith C; Smith M; Cunningham R; Davis S
    Cancer Nurs; 2020; 43(4):E217-E228. PubMed ID: 30688665
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of Palonosetron on Nausea and Vomiting Induced by Multiple-Day Chemotherapy: A Retrospective Study.
    Hamano H; Mitsuhashi C; Suzuki Y; Zamami Y; Tsujinaka K; Okada N; Niimura T; Hayama T; Imai T; Ishida S; Sakamoto K; Goda M; Takechi K; Yagi K; Chuma M; Horinouchi Y; Shinomiya K; Ikeda Y; Kirino Y; Nakamura T; Yanagawa H; Hamada Y; Ishizawa K
    Biol Pharm Bull; 2021; 44(4):478-484. PubMed ID: 33790099
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A prospective study of the antiemetic effect of palonosetron in malignant lymphoma patients treated with the CHOP regimen.
    Miyata Y; Yakushijin K; Inui Y; Imamura Y; Goto H; Mizutani Y; Kurata K; Kakiuchi S; Sanada Y; Minami Y; Kawamoto S; Yamamoto K; Ito M; Tominaga R; Gomyo H; Mizuno I; Nomura T; Kitagawa K; Sugimoto T; Murayama T; Matsuoka H; Minami H
    Int J Hematol; 2016 Dec; 104(6):682-691. PubMed ID: 27612464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.